RT Journal Article
SR Electronic
T1 Germline predisposition to pediatric Ewing sarcoma is uniquely characterized by inherited pathogenic variants in DNA damage repair genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.07.22268685
DO 10.1101/2022.01.07.22268685
A1 Gillani, Riaz
A1 Camp, Sabrina Y.
A1 Han, Seunghun
A1 Jones, Jill K.
A1 O’Brien, Schuyler
A1 Young, Erin L.
A1 Hayes, Lucy
A1 Mitchell, Gareth
A1 Fowler, Trent
A1 Gusev, Alexander
A1 Kamihara, Junne
A1 Janeway, Katherine A.
A1 Schiffman, Joshua D.
A1 Crompton, Brian D.
A1 AlDubayan, Saud H.
A1 Van Allen, Eliezer M.
YR 2022
UL http://medrxiv.org/content/early/2022/01/11/2022.01.07.22268685.abstract
AB More knowledge is needed around the role and importance of specific genes in germline predisposition to Ewing sarcoma to inform biological investigation and clinical practice. In this study, we evaluated the enrichment of pathogenic germline variants in Ewing sarcoma relative to other pediatric sarcoma subtypes, as well as patterns of inheritance of these variants. We carried out an ancestry-matched case-control analysis to screen for enrichment of pathogenic germline variants in 141 established cancer predisposition genes in 1138 individuals with pediatric sarcoma diagnoses (222 Ewing sarcoma cases) relative to identically processed cancer-free controls. Findings in Ewing sarcoma were validated with an additional cohort of 425 individuals, and 301 Ewing sarcoma parent-proband trios were analyzed for inheritance patterns of identified pathogenic variants. A distinct pattern of pathogenic germline variants was seen in Ewing sarcoma relative to other sarcoma subtypes. FANCC was the only gene with an enrichment signal for heterozygous pathogenic variants in the discovery Ewing sarcoma cohort (OR 14.4, 95% CI 3.5 – 51.2, p = 0.002, FDR = 0.28). This enrichment in FANCC heterozygous pathogenic variants was seen again in the Ewing sarcoma validation cohort (OR 5.1, 95% CI 1.2 – 18.5, p = 0.03, single hypothesis), representing a broader importance of genes involved in DNA damage repair, which were also nominally enriched in Ewing sarcoma cases. Pathogenic variants in DNA damage repair genes were acquired through autosomal inheritance. Our study provides new insight into germline risk factors contributing to Ewing sarcoma pathogenesis.Competing Interest StatementR.G. has equity in Google, Microsoft, Amazon, Moderna, Pfizer, and Vertex Pharmaceuticals. E.M.V.A. holds consulting roles with Tango Therapeutics, Invitae, Genome Medical, Enara Bio, Janssen, and Manifold Bio; he receives research support from Bristol-Myers Squibb and Novartis; he has equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, and Microsoft; he has received travel reimbursement from Roche and Genentech; and he has filed institutional patents on chromatin mutations, immunotherapy response, and methods for clinical interpretation. Other authors have no relevant disclosures.Funding StatementThis work was supported by a Research Training Grant in Pediatric Oncology NIH 5T32CA136432-12 (R.G.), American Society of Clinical Oncology Conquer Cancer - Sarcoma Foundation of America Young Investigator Award (R.G.), Jay Vernon Jackson Memorial Research Award from Sarcoma Foundation of America (R.G.), Edward B. Clark, MD Endowed Chair in Pediatric Research (J.D.S.), Helen Clise Presidential Endowed Chair in Li-Fraumeni Syndrome Research (J.D.S.), Conquer Cancer Foundation Career Development Award 13167 from the American Society of Clinical Oncology (S.H.A.), Young Investigator Award 18YOUN02 from the Prostate Cancer Foundation (S.H.A.), Physician Research Award (PC200150/W81XWH-21-1-0084) of the Department of Defense (S.H.A), NIH R37 CA222574 (E.M.V.A.), R01 CA227388 (E.M.V.A.), U01 CA233100 (E.M.V.A.), Innovation in Cancer Informatics Award (E.M.V.A.), COG Biospecimen Bank Grant U24CA196173, NCTN Operations Center Grant U10CA180886, NCTN Statistics & Data Center Grant U10CA180899, and Gabriella Miller Kids First 1X01 HL 140547-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sequencing data analyzed in this study were obtained from multiple publicly accessible data repositories. Sequenced samples from the discovery cohort came from four data sources: St. Jude Cloud, dbGaP, ICGC and Gabriella Miller Kids First. The control cohorts came from dbGaP, NHLBI, and the 1000 Genomes Project. Written informed consent from patients and institutional review board approval, allowing comprehensive genetic analysis of germline samples, were obtained by the original studies that enrolled patients. The secondary genomic and deep-learning analyses performed for this study were approved under Dana-Farber Cancer Institute institutional review board protocols 21-143 and 20-691. This study conforms to the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. Raw sequencing data is available through public data repositories as detailed in the section pertaining to source data.